Empagliflozin Not Found to Preserve Exercise Ability in Chronic Heart Failure
Empagliflozin was not found to affect the exercise ability of patients with chronic heart failure with reduced or preserved ejection fraction after 12 weeks of treatment.
Florence Chaverneff, PhD
Editor
Florence Chaverneff, PhD, is the editor for Clinical Pain Advisor at Haymarket Media. A neuroscientist by training, Florence conducted basic research investigating mechanisms underlying Alzheimer disease, schizophrenia, and multiple sclerosis, and acquired additional experience in stem cell biology.
